Search

Author/Creator Cortot, A

2. 62OTepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study. (24th November 2019)

Authors:
Park, K; Felip, E; Veillon, R; Cortot, A; Mazieres, J; Sakai, H; Reinmuth, N; Viteri, S; Chen, Y-M; Han, J-Y; Jang, T-W; Morise, M; Sakamoto, T; Tokito, T; Cho, B C; Bruns, R; Scheele, J; Straub, J; Le, X; Paik, P K
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Issue 6 (1st June 1998)

Authors:
Quinton, J-F; Sendid, B; Reumaux, D; Duthilleul, P; Cortot, A; Grandbastien, B; Charrier, G; Targan, S R; Colombel, J-F; Poulain, D
Journal:
Gut
Issue:
Volume 42:Issue 6(1998)
Page Start:
788
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. (4th October 2019)

Authors:
Moro-Sibilot, D; Cozic, N; Pérol, M; Mazières, J; Otto, J; Souquet, P J; Bahleda, R; Wislez, M; Zalcman, G; Guibert, S D; Barlési, F; Mennecier, B; Monnet, I; Sabatier, R; Bota, S; Dubos, C; Verriele, V; Haddad, V; Ferretti, G; Cortot, A
Journal:
Annals of oncology
Issue:
Volume 30:Number 12(2019)
Page Start:
1985
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗